Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Kiniksa Pharmaceuticals International filings provide 3 years of Current Deferred Revenue readings, the most recent being $31.8 million for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue rose 10261.89% to $31.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $31.8 million, a 10261.89% increase, with the full-year FY2024 number at $31.8 million, up 10261.89% from a year prior.
  • Current Deferred Revenue hit $31.8 million in Q4 2024 for Kiniksa Pharmaceuticals International, up from $12000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $31.8 million in Q4 2024 to a low of $12000.0 in Q2 2024.
  • Median Current Deferred Revenue over the past 3 years was $4.7 million (2023), compared with a mean of $7.8 million.
  • The widest YoY moves for Current Deferred Revenue: up 10261.89% in 2024, down 99.74% in 2024.
  • Kiniksa Pharmaceuticals International's Current Deferred Revenue stood at $12.0 million in 2022, then crashed by 97.44% to $307000.0 in 2023, then soared by 10261.89% to $31.8 million in 2024.
  • The last three reported values for Current Deferred Revenue were $31.8 million (Q4 2024), $12000.0 (Q2 2024), and $156000.0 (Q1 2024) per Business Quant data.